Even before it went on the market in 2002, doctors were talking about how the back surgery product known as bone morphogenetic protein-2 would revolutionize medicine. It did - but in ways no one imagined. Instead of offering 100% success in fusing ailing spines with virtually no complications, BMP-2 became a biotech breakthrough associated with skepticism and scandal, epitomizing questions over whether corporate-funded research carried out by financially conflicted doctors can be trusted.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...